Lilly continues to build cancer pipeline with AurKa acquisition

Eli Lilly and Co. (NYSE:LLY) signed another bolt-on deal to build its cancer pipeline, agreeing Monday to buy AurKa Pharma Inc. (Montreal, Quebec) for up to $575 million. The deal comes just four days after Lilly announced it will buy immuno-oncology

Read the full 417 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE